Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease

References

• Mozaffarian D, Benjamin EJ, Go AS, et al.; Writing Group M. Heart disease and stroke statistics-2016 update: a report from the American heart association. Circulation. 2016 Jan 26;133(4):e38–e60.
   PubMed Web of Science ®Google Scholar
• Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American college of cardiology foundation/American heart association task force on practice guidelines, and the American college of physicians, American association for thoracic surgery, preventive cardiovascular nurses association, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Am Coll Cardiol. 2012;60(24):2564–2603.
   PubMedGoogle Scholar
• Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with Non–ST-Elevation acute coronary syndromes: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139–e228.
   PubMed Web of Science ®Google Scholar
• O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-Elevation myocardial infarction: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol. 2013;61(4):e78–e140.
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ (Clinical Research Ed). 2004 Jul 3;329(7456):15–19.
   PubMed Web of Science ®Google Scholar
• Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002 Oct 28;162(19):2197–2202.
   PubMedGoogle Scholar
• Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ (Clinical Research Ed). 2000 Nov 11;321(7270):1183–1187.
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 Jan 12;324(7329):71–86.
   PubMed Web of Science ®Google Scholar
• McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006 Aug;119(8):624–638.
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Bhatt DL, Brennan DM, et al. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med. 2009 Mar 17;150(6):379–386.
   PubMed Web of Science ®Google Scholar
• Silvoso GR, Ivey KJ, Butt JH, et al. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med. 1979 Oct;91(4):517–520.
   PubMed Web of Science ®Google Scholar
• Petroski D. Endoscopic comparison of three aspirin preparations and placebo. Clin Ther. 1993 Mar-Apr;15(2):314–320.
   PubMed Web of Science ®Google Scholar
• Hawthorne AB, Mahida YR, Cole AT, et al. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol. 1991 Jul;32(1):77–83.
   PubMed Web of Science ®Google Scholar
• Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet (London, England). 1996 Nov 23;348(9039):1413–1416.
   PubMed Web of Science ®Google Scholar
• Tamura A, Murakami K, Kadota J. Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents: the OITA-GF study. Qjm. 2011 Feb;104(2):133–139.
   PubMed Web of Science ®Google Scholar
• Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med. 2002 Jan 28;162(2):169–175.
   PubMed Web of Science ®Google Scholar
• Ekstrom P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol. 1996 Aug;31(8):753–758.
   PubMed Web of Science ®Google Scholar
• Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther. 1998 Feb;12(2):135–140.
   PubMed Web of Science ®Google Scholar
• Lin KJ, Hernandez-Diaz S, Garcia Rodriguez LA. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology. 2011 Jul;141(1):71–79.
   PubMed Web of Science ®Google Scholar
• Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005 Jan 20;352(3):238–244.
   PubMed Web of Science ®Google Scholar
• Lai KC, Chu KM, Hui WM, et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol. 2006 Jul;4(7):860–865.
   PubMed Web of Science ®Google Scholar
• Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart (British Cardiac Society). 2011 May;97(10):797–802.
   PubMed Web of Science ®Google Scholar
• Scheiman JM, Herlitz J, Veldhuyzen van Zanten SJ, et al. Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial. J Cardiovasc Pharmacol. 2013 Mar;61(3):250–257.
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995 Aug 15;123(4):241–249.
   PubMed Web of Science ®Google Scholar
• Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med. 1995 Sep 1;123(5):344–350.
   PubMed Web of Science ®Google Scholar
• Agrawal NM, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med. 1991 Aug 1;115(3):195–200.
   PubMed Web of Science ®Google Scholar
• Raskin JB, White RH, Jaszewski R, et al. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol. 1996 Feb;91(2):223–227.
   PubMed Web of Science ®Google Scholar
• Ehsanullah RS, Page MC, Tildesley G, et al. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ (Clinical Research Ed). 1988 Oct 22;297(6655):1017–1021.
   PubMed Web of Science ®Google Scholar
• Robinson MG, Griffin JW Jr., Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci. 1989 Mar;34(3):424–428.
   PubMed Web of Science ®Google Scholar
• Ten Wolde S, Dijkmans BA, Janssen M, et al. High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs. Aliment Pharmacol Ther. 1996 Jun;10(3):347–351.
   PubMed Web of Science ®Google Scholar
• Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid suppression trial: ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) study group. N Engl J Med. 1998 Mar 12;338(11):719–726.
   PubMed Web of Science ®Google Scholar
• Koch M, Dezi A, Ferrario F, et al. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med. 1996 Nov 11;156(20):2321–2332.
   PubMedGoogle Scholar
• Taha AS, McCloskey C, Prasad R, et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2009 Jul 11;374(9684):119–125.
   PubMed Web of Science ®Google Scholar
• Graham DY. High-dose famotidine for prevention of NSAID ulcers? Gastroenterology. 1997 Jun;112(6):2143–2145.
   PubMed Web of Science ®Google Scholar
• Graham DY. Famotidine to prevent peptic ulcer caused by NSAIDs. N Engl J Med. 1996 Oct 24;335(17):1322; author reply 22-3.
   Google Scholar
• Hudson N, Taha AS, Russell RI, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology. 1997 Jun;112(6):1817–1822.
   PubMed Web of Science ®Google Scholar
• Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med. 1996 May 30;334(22):1435–1439.
   PubMed Web of Science ®Google Scholar
• Ng FH, Wong SY, Lam KF, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology. 2010 Jan;138(1):82–88.
   PubMed Web of Science ®Google Scholar
• Laine L, Kivitz AJ, Bello AE, et al. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol. 2012 Mar;107(3):379–386.
   PubMed Web of Science ®Google Scholar
• Research Center for Drug Evaluation. Postmarket Drug Safety Information for Patients and Providers – Public Health Advisory: Updated Safety Information about a drug interaction between Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole (marketed as Prilosec and Prilosec OTC) [Internet]. [cited 2016 Dec 15]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm190825.htm
   Google Scholar
• Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American college of cardiology foundation task force on clinical expert consensus documents. J Am Coll Cardiol. 2008 Oct 28;52(18):1502–1517.
   PubMed Web of Science ®Google Scholar
• Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American college of cardiology foundation task force on expert consensus documents. J Am Coll Cardiol. 2010 Dec 7;56(24):2051–2066.
   PubMed Web of Science ®Google Scholar
• Pillinger MH, Capodici C, Rosenthal P, et al. Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14540–14545.
   PubMed Web of Science ®Google Scholar
• Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984 Nov 8;311(19):1206–1211.
   PubMed Web of Science ®Google Scholar
• Tantry US, Mahla E, Gurbel PA. Aspirin resistance. Prog Cardiovasc Dis. 2009 Sep-Oct;52(2):141–152.
   PubMed Web of Science ®Google Scholar
• Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975 Aug;72(8):3073–3076.
   PubMed Web of Science ®Google Scholar
• Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol. 1995 Aug;2(8):637–643.
   PubMedGoogle Scholar
• Rubak P, Hardlei TF, Wurtz M, et al. Low-dose acetylsalicylic acid therapy monitored with ultra high performance liquid chromatography. Clin Biochem. 2013 Aug;46(12):988–992.
   PubMed Web of Science ®Google Scholar
• Tang M, Mukundan M, Yang J, et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther. 2006 Dec;319(3):1467–1476.
   PubMed Web of Science ®Google Scholar
• Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol. 1992 Aug;263(2 Pt 2):F181–F91.
   PubMedGoogle Scholar
• Hawkey CJ. COX-2 inhibitors. Lancet (London, England). 1999 Jan 23;353(9149):307–314.
   PubMed Web of Science ®Google Scholar
• Morita I, Schindler M, Regier MK, et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and −2. J Biol Chem. 1995 May 5;270(18):10902–10908.
   PubMed Web of Science ®Google Scholar
• Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 1998 Nov;114(5 Suppl):470s–488s.
   PubMed Web of Science ®Google Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232–235.
   PubMedGoogle Scholar
• Smith WL, DeWitt DL. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol. 1995 May;15(3):179–194.
   PubMed Web of Science ®Google Scholar
• Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982 Jun;69(6):1366–1372.
   PubMed Web of Science ®Google Scholar
• Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985 Dec;72(6):1177–1184.
   PubMed Web of Science ®Google Scholar
• Tohgi H, Konno S, Tamura K, et al. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke. 1992 Oct;23(10):1400–1403.
   PubMed Web of Science ®Google Scholar
• Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology. 1999 Jul;117(1):17–25.
   PubMed Web of Science ®Google Scholar
• Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet. 2000 Mar;38(3):243–270.
   PubMed Web of Science ®Google Scholar
• Shin JM, Sachs G. Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology. 2002 Nov;123(5):1588–1597.
   PubMed Web of Science ®Google Scholar
• Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000 Feb;118(2 Suppl 1):S9–S31.
   Google Scholar
• Berger PB, Bhatt DL, Fuster V, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation. 2010 Jun 15;121(23):2575–2583.
   PubMedGoogle Scholar
• Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003 Oct 7;108(14):1682–1687.
   PubMed Web of Science ®Google Scholar
• Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010 Sep 2;363(10):930–942.
   PubMed Web of Science ®Google Scholar
• Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006 Nov;27(22):2667–2674.
   PubMed Web of Science ®Google Scholar
• Sturkenboom MC, Burke TA, Tangelder MJ, et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2003 Dec;18(11–12):1137–1147.
   PubMed Web of Science ®Google Scholar
• Miner PB Jr., Fort JG, Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study. Aliment Pharmacol Ther. 2013 Jul;38(1):62–71.
   PubMed Web of Science ®Google Scholar
• Bliden KP, Brener M, Gesheff MG, et al. PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection. Future Cardiol. 2013 Nov;9(6):785–797.
   PubMedGoogle Scholar
• Lanza FL, Aspinall RL, Swabb EA, et al. Double-blind, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum. Gastroenterology. 1988 Aug;95(2):289–294.
   PubMed Web of Science ®Google Scholar
• Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008 Oct;103(10):2465–2473.
   PubMed Web of Science ®Google Scholar
• Whellan DJ, Goldstein JL, Cryer BL, et al. PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studies. Am Heart J. 2014 Oct;168(4):495–502.e4.
   PubMed Web of Science ®Google Scholar